



Suggested Formula	Methotrexate 25 mg/mL Intramuscular Injection (Solution, 10 mL)	FIN	F 004 923v3
-------------------	---	-----	-------------

SUGGESTED FORMULATION

Ingredient Listing	Qty.	Unit	NDC #	Supplier	Lot No.	Expiry Date
Methotrexate, USP	TBD					
Benzyl Alcohol (Parenteral Application), NF	0.2	mL				
Sodium Chloride, USP	0.036	g				
Sterile Water for Injection, USP	8.0	mL				
Sterile Water for Injection, USP	q.s. to 10.0	mL				
Sodium Hydroxide 10% Solution	As required					
Hydrochloric Acid 10% Solution	As required					

SPECIAL PREPARATORY CONSIDERATIONS

Ingredient-Specific Information

Light Sensitive (protect from light whenever possible): Methotrexate, Benzyl Alcohol

Hygroscopic (protect from moisture whenever possible): Methotrexate





Suggested Formula	Methotrexate 25 mg/mL Intramuscular Injection (Solution, 10 mL)	FIN	F 004 923v3
-------------------	---	-----	-------------

SPECIAL PREPARATORY CONSIDERATIONS (CONTINUED)

Suggested Preparatory Guidelines

Non-Sterile Preparation Sterile Preparation

Processing Error / Testing Considerations: To account for processing error, pH testing, sterility and endotoxin testing considerations during preparation, it is suggested to measure an additional **20 to 25%** of the required quantities of ingredients.

Special Instruction: This formula may contain one or more Active Pharmaceutical Ingredients (APIs) that may be classified as hazardous, please refer & verify the current NIOSH list of Antineoplastic and Other Hazardous Drugs in Healthcare Settings. At this time, **General Chapter <800> Hazardous Drugs – Handling in Healthcare Settings** is informational and not compendially applicable unless otherwise specified by regulators and enforcement bodies. For information on the scope, intended applicability, and implementation context for USP General Chapter <800>, see: <https://www.usp.org/compounding/general-chapter-hazardous-drugs-handling-healthcare>.

This formula must be prepared within the appropriate facilities under adequate environmental conditions, following the necessary guidelines and procedures as stated within *USP 797* and *USP 800* when handling hazardous drugs. Only trained and qualified personnel must prepare this formula.

All heat stable, reusable materials and equipment must be sterilized and depyrogenated by dry heat sterilization at 250°C for 2 hours prior to use.

Compounder needs to verify as per USP, if every batch of final product compounded using this procedure must be sterility and endotoxin tested before being dispensed.

All required personal protective equipment (sterile and hazardous if applicable), such as but not limited to, gowns, aprons, sleeves, gloves both inner and outer if applicable, shoe covers, hairnet, head cap, beard cover, eyewear, appropriate face mask, respirator and face shield, etc., where applicable must be worn at all times. In addition, proper personnel cleansing must be done before entering the buffer or clean area.

If applicable, follow all required procedures for hazardous drug handling including but not limited to procurement, transport, storage, preparation, dispensing, administration, clean up (spills) & disposal.

Filter integrity must be validated by performing a filter stress test. If the test demonstrates that the filter might be defective, the solution must be discarded and remade.

If you are a registered 503B facility, please refer to all relevant guidance documents including but not limited to the Code of Federal Regulations (CFR), Guidance for Industry (GFI) and Compliance Policy Guides (CPGs).

This procedure requires the use of very small quantities of ingredients. All calculations and preparation techniques must be verified before dispensing the final product.



Suggested Formula	Methotrexate 25 mg/mL Intramuscular Injection (Solution, 10 mL)	FIN	F 004 923v3
-------------------	---	-----	-------------

SUGGESTED PREPARATION (for 10 mL)

Weigh and / or measure the following ingredients when appropriate:

Ingredient Listing	Qty.	Unit	Multiplication factor (*): _____	Processing Error	Qty. to measure
Methotrexate, USP §	TBD				
Benzyl Alcohol (Parenteral Application), NF §	0.2	mL			
Sodium Chloride, USP §	0.036	g			
Sterile Water for Injection, USP §	8.0	mL			
Sterile Water for Injection, USP §	q.s. to 10.0	mL			
Sodium Hydroxide 10% Solution §	As required				
Hydrochloric Acid 10% Solution §	As required				

* Takes into account increased batch size conversions and density conversions, if required.

§ Weigh / measure just prior to use.





Suggested Formula	Methotrexate 25 mg/mL Intramuscular Injection (Solution, 10 mL)	FIN	F 004 923v3
-------------------	---	-----	-------------

Preparatory Instruction

IMPORTANT: All preparatory procedures must be performed using proper Aseptic Technique

1. Equipment sterilization:

Following the manufacturer's specifications, sterilize and depyrogenate all heat stable, reusable materials and equipment, then return to ambient temperature.

2. Ingredient quantification:

A. Determine the potency of Methotrexate based on the certificate of analysis:

MINUS	100%
Loss on drying (from certificate of analysis)	_____ %
DIVIDED BY	100
EQUALS	
Quantity of dried Methotrexate, in decimal	_____
MULTIPLIED BY	
Assay on dried basis result (from certificate of analysis)	_____ %
DIVIDED BY	100
EQUALS	
i. Potency of Methotrexate, in decimal	_____



Suggested Formula	Methotrexate 25 mg/mL Intramuscular Injection (Solution, 10 mL)	FIN	F 004 923v3
-------------------	---	-----	-------------

3. **Ingredient quantification:**

- A. Determine the quantity (in g) of Methotrexate required to make a 10 mL batch of Methotrexate 25 mg/mL Injection:

Quantity of Methotrexate required for a 10 mL Injection	0.250 g
DIVIDED BY	
Potency of Methotrexate, in decimal (Step 2Ai)	_____
EQUALS	_____
i. Quantity of Methotrexate needed for a 10 mL Injection	_____ g
MULTIPLIED BY	
Processing error adjustments (20 to 25%):	1.20 to 1.25
EQUALS	_____
ii. Quantity of Methotrexate needed <i>plus</i> processing error adjustments:	_____ g

4. **Powder preparation:**

- A. In the given order, sequentially add the following ingredients to the Sterile Water for Injection (8.0 mL *plus* processing error adjustments):

- Benzyl Alcohol (Parenteral Application)
- Methotrexate (amount determined in Step 3Aii)
- Sodium Chloride

Specifications: Continuously mix.

End result: Homogeneous liquid-like dispersion.

Note: Add the next ingredient, once the previous one has been completely added and dispersed.



Suggested Formula	Methotrexate 25 mg/mL Intramuscular Injection (Solution, 10 mL)	FIN	F 004 923v3
-------------------	---	-----	-------------

5.	<p><u>pH testing:</u></p> <p>A. Draw an appropriate amount of the mixture (Step 4A).</p> <p>B. Test the pH of the sample. It should lie between 8.3 and 8.6.</p> <p>C. <u>If the pH < 8.3, carefully add, in a dropwise fashion, the Sodium Hydroxide 10% Solution to the mixture:</u></p> <ol style="list-style-type: none">1. Draw and transfer 1 or 2 drops of the Sodium Hydroxide 10% Solution to the mixture.2. Stir for at least 5 minutes to evenly disperse the Sodium Hydroxide 10% Solution.3. Re-test the pH.4. Continue to add the Sodium Hydroxide 10% Solution until the pH of 8.3 to 8.6 is obtained. <p>IMPORTANT: Do not allow the pH to rise above 8.6.</p> <p>D. <u>If the pH > 8.6, carefully add, in a dropwise fashion, the Hydrochloric Acid 10% Solution to the mixture:</u></p> <ol style="list-style-type: none">1. Draw and transfer 1 or 2 drops of the Hydrochloric Acid 10% Solution to the mixture.2. Stir for at least 5 minutes to evenly disperse the Hydrochloric Acid 10% Solution.3. Re-test the pH.4. Continue to add the Hydrochloric Acid 10% Solution until the pH of 8.3 to 8.6 is obtained. <p>IMPORTANT: Do not allow the pH to fall below 8.3.</p> <p><u>End result:</u> Homogeneous liquid-like <u>solution</u>.</p>
6.	<p><u>Filling to volume:</u></p> <p>A. Add additional Sterile Water for Injection to the above mixture to fill to the required batch size (10.0 mL <i>plus</i> processing error adjustments).</p> <p><u>Specifications:</u> Continuously mix.</p> <p><u>End result:</u> Homogeneous liquid-like solution.</p>
7.	<p><u>Filtering and transferring:</u></p> <p>Aseptically filter the solution through a 0.22-μm sterile filter into the recommended dispensing container (see Packaging requirements). Transfer the remainder into a separate dispensing container. This is to be used as the Test sample for sterility and endotoxin testing.</p>
8.	<p><u>Filter integrity test:</u></p> <p>Validate filter integrity by performing a filter stress test. If the test demonstrates that the filter might be defective, the solution must be discarded and remade.</p>



Suggested Formula	Methotrexate 25 mg/mL Intramuscular Injection (Solution, 10 mL)	FIN	F 004 923v3
-------------------	---	-----	-------------

9.	<p><u>Terminal Sterilization:</u></p> <p>In relation to the chemical composition of the formulation, final packaging, etc., select and validate an end-stage sterilization method and follow the manufacturer's specifications.</p>
10.	<p><u>Sterility and Endotoxin testing:</u></p> <p>Validate the Test sample for sterility and endotoxins, in accordance to current USP 797 regulatory guidelines.</p>

SUGGESTED PRESENTATION

Estimated Beyond-Use Date	24 hours controlled room temperature, 3 days refrigerated, or 45 days frozen, as per USP 797. BUD based on successful endotoxin test result.	Packaging Requirements	Sterile, tightly closed, light-resistant injection vials.
Auxiliary Labels	1 Use as directed. Do not exceed prescribed dose.	7	Discard in the presence of particulate matter.
	2 Keep out of reach of children.	8	Do not use if product changes color.
	3 Equilibrate to room temperature before use.	9	Consult your health care practitioner if any prescription or over-the-counter medications are currently being used or are prescribed for future use.
	4 Protect from light.	10	Discard container after use.
	5 Keep at controlled room temperature, (20°C – 25°C), refrigerated (2°C – 8°C) or frozen (-25°C to -10°C).	11	May impair mental and/or physical ability. Use care when operating a car or machinery.
	6 Do not take with alcohol, sleep aids, tranquilizers or other CNS depressants.		
Pharmacist Instructions	Add any auxiliary labels specific to the API to the dispensing container as deemed necessary.		
Patient Instructions	Contact your pharmacist in the event of adverse reactions.		



Suggested Formula	Methotrexate 25 mg/mL Intramuscular Injection (Solution, 10 mL)	FIN	F 004 923v3
-------------------	---	-----	-------------

REFERENCES

1.	Parenteral Preparations. In: Allen, LV, Jr. <i>The Art, Science and Technology of Pharmaceutical Compounding Third Edition</i> . American Pharmaceutical Association; 2008: 313.
2.	Methotrexate Injection USP. In: Canadian Pharmacists Association. <i>Compendium of Pharmacists and Specialties, 2011</i> : 1511.
3.	Benzyl Alcohol. In: Rowe RC. <i>Handbook of Pharmaceutical Excipients, 6th Edition</i> . American Pharmaceutical Association; 2009: 64.
4.	Sodium Chloride. In: Rowe RC. <i>Handbook of Pharmaceutical Excipients, 6th Edition</i> . American Pharmaceutical Association; 2009: 637.
5.	Methotrexate. In: Sweetman SC, ed. <i>Martindale: The Complete Drug Reference, 36th Edition</i> . London, England: The Pharmaceutical Press; 2009: 745.
6.	Methotrexate (Monograph). In: O'Neil MJ. <i>The Merck Index 14th Edition</i> . Whitehouse Station, NJ: Merck & Co, Inc.; 2006: Monograph #5985.
7.	Methotrexate (Monograph). <i>United States Pharmacopeia XXXIV / National Formulary 29</i> . Rockville, MD. US Pharmacopeial Convention, Inc. 2011: 3466.
8.	Methotrexate for Cancer Systemic. Thomson Micromedex. <i>USP DI – Drug Information for the Health Care Professional, 26th Edition</i> . Taunton, MA: US Pharmacopeial Convention, Inc; 2006: 2041.
9.	Chapter 8: Buffered and Isotonic Solutions. In: Martin, A. <i>Physical Pharmacy, Fourth Edition</i> . Philadelphia, PA: Lippincott Williams & Wilkins; 1993: 169~189.
10.	Chapter 18: Tonicity, Osmoticity, Osmolality and Osmolarity. In: D.B Troy. <i>Remington: The Science and Practice of Pharmacy, 21st Edition</i> . Baltimore, MD: Lippincott Williams & Wilkins; 2006: 250~265
11.	USP <797>. <i>United States Pharmacopeia XXXIV / National Formulary 29</i> . Rockville, MD. US Pharmacopeial Convention, Inc. 2011: 336.

DISCLAIMER: THIS DOCUMENT IS COPYRIGHT© 2019-2020 MEDISCA PHARMACEUTIQUE INC. MEDISCA NETWORK INC., HEREBY REFERRED TO AS 'THE NETWORK', HAS PROVIDED THE FORMULA AND INSTRUCTIONS ABOVE AS A MODEL FOR EDUCATIONAL PURPOSES ONLY ON THE BASIS OF THE RECOGNIZED COMPENDIA AND TEXTS REFERENCED AT THE END OF THIS DOCUMENT. THE NETWORK TAKES NO RESPONSIBILITY FOR THE VALIDITY, SCHEDULING OR ACCURACY OF THIS INFORMATION OR FOR ITS SAFETY OR EFFECTIVENESS, NOR FOR ANY USE THEREOF, WHICH IS AT THE SOLE RISK OF THE LICENSED PHARMACIST OR OTHER APPROPRIATELY STATE LICENSED PROFESSIONAL. ADJUSTMENTS MAY BE NEEDED TO MEET SPECIFIC PATIENT NEEDS AND IN ACCORDANCE WITH A LICENSED PRESCRIBER'S PRESCRIPTION. THE PHARMACIST OR OTHER APPROPRIATELY STATE LICENSED PROFESSIONAL MUST EMPLOY APPROPRIATE TESTS TO DETERMINE THE STABILITY OF THIS SUGGESTED FORMULA. THE NETWORK CANNOT BE HELD LIABLE TO ANY PERSON OR ENTITY CONCERNING CLAIMS, LOSS, OR DAMAGE CAUSED BY, OR ALLEGED TO BE CAUSED BY, DIRECTLY OR INDIRECTLY, THE USE OR MISUSE OF THE INFORMATION CONTAINED IN THIS SUGGESTED FORMULA. IN ALL CASES IT IS THE RESPONSIBILITY OF THE LICENSED PHARMACIST OR OTHER APPROPRIATELY STATE LICENSED PROFESSIONAL TO KNOW THE LAW, TO COMPOUND ANY FINISHED PRODUCT AND TO DISPENSE THESE PRODUCTS IN ACCORDANCE WITH FEDERAL AND STATE LAW. MEDISCA NETWORK INC. MAKES NO WARRANTIES WITH RESPECT TO INFRINGEMENT OR NON-INFRINGEMENT BY THE FORMULA OF ANY PATENT OR OTHER INTELLECTUAL PROPERTY OF ANY OTHER PARTY, AND IT IS THE RESPONSIBILITY OF THE PHARMACIST OR OTHER APPROPRIATELY STATE LICENSED PROFESSIONAL TO INVESTIGATE AND DETERMINE ANY SUCH ISSUE.